{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:21:31Z","timestamp":1794432091323,"version":"4.9.1"},"reference-count":59,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Innovation of Spain","award":["PID2022-1381850B-I00"],"award-info":[{"award-number":["PID2022-1381850B-I00"]}]},{"name":"Ministry of Science and Innovation of Spain","award":["FI17\/00282"],"award-info":[{"award-number":["FI17\/00282"]}]},{"name":"Ministry of Science and Innovation of Spain","award":["BIO-0139"],"award-info":[{"award-number":["BIO-0139"]}]},{"name":"Instituto de Salud Carlos III","award":["PID2022-1381850B-I00"],"award-info":[{"award-number":["PID2022-1381850B-I00"]}]},{"name":"Instituto de Salud Carlos III","award":["FI17\/00282"],"award-info":[{"award-number":["FI17\/00282"]}]},{"name":"Instituto de Salud Carlos III","award":["BIO-0139"],"award-info":[{"award-number":["BIO-0139"]}]},{"name":"European Union","award":["PID2022-1381850B-I00"],"award-info":[{"award-number":["PID2022-1381850B-I00"]}]},{"name":"European Union","award":["FI17\/00282"],"award-info":[{"award-number":["FI17\/00282"]}]},{"name":"European Union","award":["BIO-0139"],"award-info":[{"award-number":["BIO-0139"]}]},{"name":"Junta de Andalucia","award":["PID2022-1381850B-I00"],"award-info":[{"award-number":["PID2022-1381850B-I00"]}]},{"name":"Junta de Andalucia","award":["FI17\/00282"],"award-info":[{"award-number":["FI17\/00282"]}]},{"name":"Junta de Andalucia","award":["BIO-0139"],"award-info":[{"award-number":["BIO-0139"]}]},{"name":"CIBERobn","award":["PID2022-1381850B-I00"],"award-info":[{"award-number":["PID2022-1381850B-I00"]}]},{"name":"CIBERobn","award":["FI17\/00282"],"award-info":[{"award-number":["FI17\/00282"]}]},{"name":"CIBERobn","award":["BIO-0139"],"award-info":[{"award-number":["BIO-0139"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alternative splicing dysregulation is an emerging cancer hallmark, potentially serving as a source of novel diagnostic, prognostic, or therapeutic tools. Inhibitors of the activity of the splicing machinery can exert antitumoral effects in cancer cells. We aimed to characterize the splicing machinery (SM) components in oral squamous cell carcinoma (OSCC) and to evaluate the direct impact of the inhibition of SM-activity on OSCC-cells. The expression of 59 SM-components was assessed using a prospective case-control study of tumor and healthy samples from 37 OSCC patients, and the relationship with clinical and histopathological features was assessed. The direct effect of pladienolide-B (SM-inhibitor) on the proliferation rate of primary OSCC cell cultures was evaluated. A significant dysregulation in several SM components was found in OSCC vs. adjacent-healthy tissues [i.e., 12 out of 59 (20%)], and their expression was associated with clinical and histopathological features of less aggressiveness and overall survival. Pladienolide-B treatment significantly decreased OSCC-cell proliferation. Our data reveal a significantly altered expression of several SM-components and link it to pathophysiological features, reinforcing a potential clinical and pathophysiological relevance of the SM dysregulation in OSCC. The inhibition of SM-activity might be a therapeutic avenue in OSCC, offering a clinically relevant opportunity to be explored.<\/jats:p>","DOI":"10.3390\/ijms25136929","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:19:26Z","timestamp":1719461966000},"page":"6929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Splicing Machinery Is Impaired in Oral Squamous Cell Carcinomas and Linked to Key Pathophysiological Features"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7188-8965","authenticated-orcid":false,"given":"Alba","family":"Sanjuan-Sanjuan","sequence":"first","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain"},{"name":"Oral and Maxillofacial Surgery Department, HURS, 14004 Cordoba, Spain"},{"name":"Oral and Maxillofacial Surgery Department, CAMC Hospital, Charleston, WV 25301, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Alors-Perez","sequence":"additional","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain"},{"name":"Department of Cell Biology, Physiology, and Immunology, University of Cordoba, 14014 Cordoba, Spain"},{"name":"CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Sanchez-Fr\u00edas","sequence":"additional","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain"},{"name":"Anatomical Pathology Service, IMIBIC\/HURS, 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Monserrat-Barbudo","sequence":"additional","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain"},{"name":"Oral and Maxillofacial Surgery Department, HURS, 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-3625","authenticated-orcid":false,"given":"Mabel","family":"Falguera Uceda","sequence":"additional","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain"},{"name":"Oral and Maxillofacial Surgery Department, HURS, 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Heredero-Jung","sequence":"additional","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain"},{"name":"Oral and Maxillofacial Surgery Department, HURS, 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7585-1913","authenticated-orcid":false,"given":"Ra\u00fal M.","family":"Luque","sequence":"additional","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain"},{"name":"Department of Cell Biology, Physiology, and Immunology, University of Cordoba, 14014 Cordoba, Spain"},{"name":"CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tibs.2015.11.003","article-title":"The Spliceosome: The Ultimate RNA Chaperone and Sculptor","volume":"41","author":"Papasaikas","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/onc.2013.570","article-title":"Alternative splicing in cancer: Implications for biology and therapy","volume":"34","author":"Chen","year":"2015","journal-title":"Oncogene"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/dna.2019.4644","article-title":"Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma","volume":"38","author":"Xing","year":"2019","journal-title":"DNA Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.oraloncology.2013.03.431","article-title":"The landscape of alternative splicing in buccal mucosa squamous cell carcinoma","volume":"49","author":"Shah","year":"2013","journal-title":"Oral Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12935-020-01249-0","article-title":"Prognostic role of alternative splicing events in head and neck squamous cell carcinoma","volume":"20","author":"Ding","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Dlamini, Z., Alaouna, M., Mbatha, S., Bhayat, A., Mabongo, M., Chatziioannou, A., and Hull, R. (2021). Genetic drivers of head and neck squamous cell carcinoma: Aberrant splicing events, mutational burden, hpv infection and future targets. Genes, 12.","DOI":"10.3390\/genes12030422"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15384047.2016.1139234","article-title":"Dysregulation of splicing proteins in head and neck squamous cell carcinoma","volume":"17","author":"Radhakrishnan","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.gene.2012.11.079","article-title":"RNA-Seq reveals differentially expressed isoforms and novel splice variants in buccal mucosal cancer","volume":"516","author":"Jakhesara","year":"2013","journal-title":"Gene"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15836","DOI":"10.1002\/jcp.28241","article-title":"Systematic analysis of survival-associated alternative splicing signatures uncovers prognostic predictors for head and neck cancer","volume":"234","author":"Liang","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7150\/ijms.14871","article-title":"Expression of SRSF3 is correlated with carcinogenesis and progression of oral squamous cell carcinoma","volume":"13","author":"Peiqi","year":"2016","journal-title":"Int. J. Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00280-019-03945-9","article-title":"Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment","volume":"84","author":"Sun","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bbamcr.2018.05.017","article-title":"SRSF5 functions as a novel oncogenic splicing factor and is upregulated by oncogene SRSF3 in oral squamous cell carcinoma","volume":"1865","author":"Yang","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/jcp.24956","article-title":"Oral squamous cancer cell exploits hnRNP A1 to regulate cell cycle and proliferation","volume":"230","author":"Yu","year":"2015","journal-title":"J. Cell Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/ijc.24517","article-title":"Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma","volume":"125","author":"Matta","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/sj.bjc.6603911","article-title":"Evidence for heterogeneous nuclear ribonucleoprotein K overexpression in oral squamous cell carcinoma","volume":"97","author":"Roychoudhury","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.7150\/jca.44746","article-title":"Identification and validation of an alternative splicing-based prognostic signature for head and neck squamous cell carcinoma","volume":"11","author":"Zhao","year":"2020","journal-title":"J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.7150\/thno.36585","article-title":"Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment","volume":"9","author":"Li","year":"2019","journal-title":"Theranostics"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Li, Z., Chen, X., Wei, M., Liu, G., Tian, Y., Zhang, X., Zhu, G., Chen, C., Liu, J., and Wang, T. (2020). Systemic Analysis of RNA Alternative Splicing Signals Related to the Prognosis for Head and Neck Squamous Cell Carcinoma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00087"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.gene.2012.07.036","article-title":"Identification of novel transcripts deregulated in buccal cancer by RNA-seq","volume":"507","author":"Sajnani","year":"2012","journal-title":"Gene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/biof.1722","article-title":"Integrated analysis of the prognostic values of RNA-binding proteins in head and neck squamous cell carcinoma","volume":"47","author":"Wu","year":"2021","journal-title":"BioFactors"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sharma, V., Nandan, A., Singh, H., Agarwal, S., Tripathi, R., Sinha, D.N., and Mehrotra, R. (2019). Events of alternative splicing in head and neck cancer via RNA sequencing\u2014An update. BMC Genom., 20.","DOI":"10.1186\/s12864-019-5794-y"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cell.2013.02.034","article-title":"Dynamic integration of splicing within gene regulatory pathways","volume":"152","author":"Braunschweig","year":"2013","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1101\/gad.1973010","article-title":"Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged","volume":"24","author":"David","year":"2010","journal-title":"Genes Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1002\/jcp.29357","article-title":"Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma","volume":"235","author":"Zhang","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1101\/gr.199935.115","article-title":"Large-Scale Analysis of Genome and Transcriptome Alterations in Multiple Tumors Unveils Novel Cancer-Relevant Splicing Networks","volume":"26","author":"Singh","year":"2016","journal-title":"Genome Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pagliarini, V., Naro, C., and Sette, C. (2015). Splicing regulation: A molecular device to enhance cancer cell adaptation. Biomed. Res. Int.","DOI":"10.1155\/2015\/543067"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trsl.2022.08.016","article-title":"Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes","volume":"253","author":"Closa","year":"2023","journal-title":"Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd3823","article-title":"The spliceosome as a target of novel antitumour drugs","volume":"11","author":"Bonnal","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_29","first-page":"3477148","article-title":"Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy","volume":"2022","author":"Liu","year":"2022","journal-title":"J. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Yadav, S., Pant, D., Samaiya, A., Kalra, N., Gupta, S., and Shukla, S. (2021). ERK1\/2-EGR1-SRSF10 Axis Mediated Alternative Splicing Plays a Critical Role in Head and Neck Cancer. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.713661"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12967-015-0637-3","article-title":"Nuclear heterogeneous nuclear ribonucleoprotein D is associated with poor prognosis and interactome analysis reveals its novel binding partners in oral cancer","volume":"13","author":"Kumar","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cao, R., Zhang, J., Jiang, L., Wang, Y., Ren, X., Cheng, B., and Xia, J. (2020). Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Oral Squamous Cell Carcinoma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01740"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35976","DOI":"10.1038\/srep35976","article-title":"HnRNP L is important for the expression of oncogene SRSF3 and oncogenic potential of oral squamous cell carcinoma cells","volume":"6","author":"Jia","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27386","DOI":"10.1074\/jbc.M114.589432","article-title":"Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms","volume":"289","author":"Ishii","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ejca.2006.09.001","article-title":"Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas","volume":"43","author":"Martinez","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11231","DOI":"10.1038\/s41598-019-47755-8","article-title":"NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s13046-021-02153-9","article-title":"Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug","volume":"40","author":"Mafficini","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Borrego, M.C., Fuentes-Fayos, A.C., Venegas-Moreno, E., Rivero-Cort\u00e9s, E., Dios, E., Moreno-Moreno, P., Madrazo-Atutxa, A., Rem\u00f3n, P., Solivera, J., and Wildemberg, L.E. (2019). Splicing machinery is dysregulated in pituitary neuroendocrine tumors and is associated with aggressiveness features. Cancers, 11.","DOI":"10.3390\/cancers11101439"},{"key":"ref_39","first-page":"3273","article-title":"Splicing machinery dysregulation drives glioblastoma development\/aggressiveness: Oncogenic role of SRSF3","volume":"143","author":"Bejarano","year":"2021","journal-title":"Brain"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2020.10.010","article-title":"Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma","volume":"496","author":"Amado","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Best, A., Dagliesh, C., Ehrmann, I., Kheirollahi-Kouhestani, M., Tyson-Capper, A., and Elliott, D.J. (2013). Expression of Tra2 \u03b2 in Cancer Cells as a Potential Contributory Factor to Neoplasia and Metastasis. Int J Cell Biol., 2013.","DOI":"10.1155\/2013\/843781"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sanjuan-Sanjuan, A., Alors-Perez, E., Sanchez-Fr\u00edas, M., Dean-Ferrer, A., Gahete, M.D., Heredero-Jung, S., and Luque, R.M. (2021). Molecular and clinical implications of somatostatin receptor profile and somatostatin analogues treatment in oral cavity squamous cell carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13194828"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.trsl.2019.07.001","article-title":"Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer","volume":"212","year":"2019","journal-title":"Transl. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-19-2154","article-title":"A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors","volume":"26","author":"Gupta","year":"2020","journal-title":"Clin Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.oraloncology.2014.03.009","article-title":"25 year survival outcomes for squamous cell carcinomas of the head and neck: Population-based outcomes from a Canadian province","volume":"50","author":"Tiwana","year":"2014","journal-title":"Oral Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3322\/caac.21293","article-title":"Oral cavity and oropharyngeal squamous cell carcinoma\u2014An update","volume":"65","author":"Chi","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","article-title":"RNA splicing dysregulation and the hallmarks of cancer","volume":"23","author":"Bradley","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrc.2016.51","article-title":"RNA splicing factors as oncoproteins and tumour suppressors","volume":"16","author":"Dvinge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Vacas, J.M., Herrero-Aguayo, V., Montero-Hidalgo, A.J., G\u00f3mez-G\u00f3mez, E., Fuentes-Fayos, A.C., Le\u00f3n-Gonz\u00e1lez, A.J., S\u00e1ez-Mart\u00ednez, P., Alors-P\u00e9rez, E., Pedraza-Ar\u00e9valo, S., and Gonz\u00e1lez-Serrano, T. (2020). Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer: SNRNP200, SRSF3 and SRRM1 as novel therapeutic targets for prostate cancer. EBioMedicine, 51.","DOI":"10.1016\/j.ebiom.2019.11.008"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1102","DOI":"10.1002\/ctm2.1102","article-title":"Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing","volume":"12","author":"Amado","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41419-021-04063-2","article-title":"Alternatively spliced ANLN isoforms synergistically contribute to the progression of head and neck squamous cell carcinoma","volume":"12","author":"Guo","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2017.03.013","article-title":"Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer","volume":"396","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100728","DOI":"10.1016\/j.drup.2020.100728","article-title":"The role of alternative splicing in cancer: From oncogenesis to drug resistance","volume":"53","author":"Sciarrillo","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ladomery, M. (2013). Aberrant alternative splicing is another hallmark of cancer. Int. J. Cell Biol., 2013.","DOI":"10.1155\/2013\/463786"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1038\/onc.2013.533","article-title":"Hallmarks of alternative splicing in cancer","volume":"33","author":"Oltean","year":"2014","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cell.2019.12.011","article-title":"SnapShot: Splicing Alterations in Cancer","volume":"180","author":"Rahman","year":"2020","journal-title":"Cell."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.canlet.2015.01.037","article-title":"Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas","volume":"359","author":"Luque","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1210\/jc.2013-1992","article-title":"A cellular and molecular basis for the selective desmopressin-induced ACTH release in cushing disease patients: Key role of AVPR1b receptor and potential therapeutic implications","volume":"98","author":"Luque","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ebiom.2018.10.056","article-title":"Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study","volume":"37","author":"Gahete","year":"2018","journal-title":"EBioMedicine"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/6929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:03:55Z","timestamp":1760108635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/6929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":59,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25136929"],"URL":"https:\/\/doi.org\/10.3390\/ijms25136929","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}